Literature DB >> 28540757

Association of Tuberculosis Status with Neurologic Disease and Immune Response in HTLV-1 Infection.

Anselmo Souza1,2, Natália Carvalho1,2, Yuri Neves1,3, Silvane Braga Santos1,2,4, Maria de Lourdes Bastos1,3, Sérgio Arruda5, Eduardo Martins Netto6, Marshall J Glesby7, Edgar Carvalho1,2,5.   

Abstract

The human T cell lymphotropic virus type 1 (HTLV-1) is the etiologic agent of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). HTLV-1 infected individuals have increased susceptibility to Mycobacterium tuberculosis infection but the influence of tuberculosis (TB) on the course of HTLV-1 infection is unknown. The aim of this study was to evaluate the influence of TB on immunological, virologic, and neurologic features of HTLV-1 infection. This is a retrospective analysis of individuals enrolled in a cohort study from an HTLV-1 clinic who were evaluated for past or latent tuberculosis (LTB) and classified clinically as HTLV-1 carriers, probable HAM/TSP and definite HAM/TSP. Spontaneous cytokine production (interferon-gamma [IFN-γ], tumor necrosis factor [TNF], and interleukin[IL]-10), serum chemokines (CXCL9 and CXCL10) and HTLV-1 proviral load were evaluated. Of 172 participants, 64 did not have histories of TB (TB- group), 81 had LTB and 27 had TB in the past (TB+ group). In the TB+ group, there was a higher frequency of HAM/TSP patients (35%) than in HTLV-1 carriers (10%) (OR = 3.8, p = .0001). HAM/TSP patients with histories of TB had higher IFN-γ/IL-10 and TNF/IL-10 ratios when compared with HAM/TSP patients without histories of TB. There were no differences in serum chemokine production and proviral load across TB groups stratified on HTLV-1 clinical status. In conclusion, TB may influence the development of HAM/TSP, and patients with these two diseases have an impairment in the modulation of immune response.

Entities:  

Keywords:  HTLV-1; immune response; tuberculosis

Mesh:

Substances:

Year:  2017        PMID: 28540757      PMCID: PMC5665362          DOI: 10.1089/AID.2015.0340

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  38 in total

1.  Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP.

Authors:  M Nagai; K Usuku; W Matsumoto; D Kodama; N Takenouchi; T Moritoyo; S Hashiguchi; M Ichinose; C R Bangham; S Izumo; M Osame
Journal:  J Neurovirol       Date:  1998-12       Impact factor: 2.643

2.  Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM).

Authors:  Carlos M De Castro-Costa; Abelardo Q C Araújo; Márcio M Barreto; Osvaldo M Takayanagui; Marzia P Sohler; Eduardo L M da Silva; Sônia M B de Paula; Ricardo Ishak; João G R Ribas; Luis C Rovirosa; Herwig Carton; Eduardo Gotuzzo; William W Hall; Silvia Montano; Edward L Murphy; Joel Oger; Carlos Remondegui; Graham P Taylor
Journal:  AIDS Res Hum Retroviruses       Date:  2006-10       Impact factor: 2.205

3.  IL-10 produced by CD4+ and CD8+ T cells emerge as a putative immunoregulatory mechanism to counterbalance the monocyte-derived TNF-alpha and guarantee asymptomatic clinical status during chronic HTLV-I infection.

Authors:  G E A Brito-Melo; V Peruhype-Magalhães; A Teixeira-Carvalho; E F Barbosa-Stancioli; A B F Carneiro-Proietti; B Catalan-Soares; J G Ribas; O A Martins-Filho
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

4.  Levels of serum chemokines discriminate clinical myelopathy associated with human T lymphotropic virus type 1 (HTLV-1)/tropical spastic paraparesis (HAM/TSP) disease from HTLV-1 carrier state.

Authors:  J B Guerreiro; S B Santos; D J Morgan; A F Porto; A L Muniz; J L Ho; A L Teixeira; M M Teixeira; E M Carvalho
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

5.  Immunological and viral features in patients with overactive bladder associated with human T-cell lymphotropic virus type 1 infection.

Authors:  Silvane Braga Santos; Paulo Oliveira; Tania Luna; Anselmo Souza; Márcia Nascimento; Isadora Siqueira; Davi Tanajura; André Luiz Muniz; Marshall J Glesby; Edgar M Carvalho
Journal:  J Med Virol       Date:  2012-11       Impact factor: 2.327

6.  Peripheral blood mononuclear cells from individuals infected with human T-cell lymphotropic virus type 1 have a reduced capacity to respond to recall antigens.

Authors:  Rita Elizabeth Mascarenhas; Cláudia Brodskyn; Geisa Barbosa; Jorge Clarêncio; Antônio Souza Andrade-Filho; Frederico Figueiroa; Bernardo Galvão-Castro; Fernanda Grassi
Journal:  Clin Vaccine Immunol       Date:  2006-05

7.  Decreased reactivity to PPD among HTLV-I carriers in relation to virus and hematologic status.

Authors:  S L Welles; N Tachibana; A Okayama; S Shioiri; S Ishihara; K Murai; N E Mueller
Journal:  Int J Cancer       Date:  1994-02-01       Impact factor: 7.396

8.  Immunological findings in neurological diseases associated with antibodies to HTLV-I: activated lymphocytes in tropical spastic paraparesis.

Authors:  S Jacobson; V Zaninovic; C Mora; P Rodgers-Johnson; W A Sheremata; C J Gibbs; C Gajdusek; D E McFarlin
Journal:  Ann Neurol       Date:  1988       Impact factor: 10.422

9.  Increased expression of human T lymphocyte virus type I (HTLV-I) Tax11-19 peptide-human histocompatibility leukocyte antigen A*201 complexes on CD4+ CD25+ T Cells detected by peptide-specific, major histocompatibility complex-restricted antibodies in patients with HTLV-I-associated neurologic disease.

Authors:  Yoshihisa Yamano; Cyril J Cohen; Norihiro Takenouchi; Karen Yao; Utano Tomaru; Hong-Chuan Li; Yoram Reiter; Steven Jacobson
Journal:  J Exp Med       Date:  2004-05-10       Impact factor: 14.307

10.  Exacerbated inflammatory cellular immune response characteristics of HAM/TSP is observed in a large proportion of HTLV-I asymptomatic carriers.

Authors:  Silvane Braga Santos; Aurélia Fonseca Porto; André Luiz Muniz; Amélia Ribeiro de Jesus; Elza Magalhães; Ailton Melo; Walderez O Dutra; Kenneth J Gollob; Edgar M Carvalho
Journal:  BMC Infect Dis       Date:  2004-03-02       Impact factor: 3.090

View more
  2 in total

Review 1.  HTLV-1 and Co-infections.

Authors:  Carolina Rosadas; Graham P Taylor
Journal:  Front Med (Lausanne)       Date:  2022-02-03

2.  Making Visible HTLV Infection in a Non-endemic Area of Argentina.

Authors:  Federico R Simioli; Maria B Bouzas; Dana Mijalovsky; Maria V Pineda; Lilia Mammana; Andrea Mangano; Tomas A Orduna
Journal:  Front Med (Lausanne)       Date:  2022-07-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.